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Glioblastoma (GBM) is a highly aggressive and lethal brain cancer with a median survival of less than two years after diagnosis.
Hallmarks of GBM tumors include soaring proliferative indices, high levels of angiogenesis, diﬀuse invasion into normal
brain parenchyma, resistance toward therapy-induced apoptosis, and pseudopallisading necrosis. Despite the recent advances in
neurosurgery, radiation therapy, and the development of targeted chemotherapeutic regimes, GBM remains one of the deadliest
types of cancer. Particularly, the alkylating agent temozolomide (TMZ) in combination with radiation therapy prolonged patient
survivalonlymarginally,andclinicalstudiesassessingeﬃcaciesoftargetedtherapies,foremostATPmimeticsinhibitingtheactivity
ofreceptortyrosinekinases(RTKs),revealedonlyfewinitialresponders;tumorrecurrenceisnearlyuniversal,andsalvagetherapies
to combat such progression remain ineﬀective. Consequently, myriad preclinical and clinical studies began to deﬁne the molecular
mechanisms underlying therapy resistance of GBM tumors, and pointed to the Bcl-2 protein family, in particular the atypical
member Bcl2-Like 12 (Bcl2L12), as important regulators of therapy-induced cell death. This review will discuss the multi-faceted
modi operandi of Bcl-2 family proteins, describe their roles in therapy resistance of malignant glioma, and outline current and
future drug development eﬀorts to therapeutically target Bcl-2 proteins.
1. MalignantAstrocyticGliomas—Scope
of the Problem
Primary brain and CNS tumors are one of the deadliest
human cancers. Based on histological, immunohistochemi-
cal, and ultrastructural criteria, the more common astrocytic
tumors are graded as pilocytic astrocytoma, grade I; astro-
cytoma, grade II; anaplastic astrocytoma, grade III; glioblas-
toma (GBM), grade IV [1]. Patients diagnosed with GBM,
the most prevalent and aggressive form of malignant glioma,
survive for a mere 12–15 months and suﬀer from seizures,
visual, cognitive, and overall physical decline, memory loss,
and personality changes, which drastically impact quality
of life [2]. Unfortunately, this dismal prognosis has not
changed signiﬁcantly over the past decades and candidly
revealed the major challenges in disease management: (i) the
highly aggressive and inﬁltrating growth of GBM tumors,
w h i c ha l m o s ta l w a y sp r e v e n t sc o m p l e t es u r g i c a lr e s e c t i o n ,
(ii) the intense resistance of GBM cells toward therapy-
induced apoptosis, and (iii) the ineﬃcient penetration
of chemotherapeutic drugs across the blood-brain barrier
(BBB), and blood-tumor barrier (BTB), toward distal sites
of tumor growth.
Numerous studies focused on deﬁning genomic, genetic,
and proteomic aberrations in GBM tumors, which cause or
contribute to the phenotypic hallmarks of the disease, that
is, soaring proliferation, apoptosis resistance, necrogenesis,
and diﬀuse invasion. In this paper, we will focus on Bcl-2
family proteins, which emerged as important antiapoptotic
proteins limiting the eﬀectiveness of conventional and
molecularly targeted therapeutics. We will describe the
complex modi operandi of canonical and atypical Bcl-2
proteins, discuss current strategies to modulate the activity
of critical family members for the treatment of malignant2 The Scientiﬁc World Journal
glioma,andconcludewithanoutlookonfuturechallengesto
conclusivelytranslatesuchbasicandtranslationalknowledge
into clinical application.
2. The Bcl-2 ProteinFamily—Many White
anda Few Black Sheep
Apoptosis plays fundamental roles in embryogenesis,
immune system homeostasis, and in diverse pathological
conditions including cardiovascular, neurological, autoim-
mune, sepsis-related, and neoplastic disorders [3]. Evad-
ing apoptosis by upregulation of antiapoptotic or down-
regulation of proapoptotic proteins is an important step
in gliomagenesis and determines susceptibility to various
chemotherapy and radiation modalities. Members of the B-
cell CLL/Lymphoma (Bcl)-2 family of proteins as prominent
regulators of apoptosis signaling are often misappropriated
in many cancers, including lung carcinoma, lymphoma [4–
6], and GBM (see below), and consequently emerged as
therapeutic targets. Bcl-2 proteins are characterized by the
presence of at least one of four Bcl-2 homology domains
(amino acid sequence LxxxGD; BH1–BH4). Based on their
domain structure and function, the Bcl-2 family is divided
into three subfamilies (Figure 1). The ﬁrst “core” subfam-
ily contains proteins that possess four BH domains and
exhibit antiapoptotic functions, such as prototypic Bcl-2
and Bcl-xL. Additional members include Bcl-w, A1, Mcl-
1, Bcl2L13/Bcl-rambo, Boo/Diva/Bcl-b/Bcl2L10, and Bcl-g.
The second subfamily consists of proapoptotic proteins,
which contain multiple BH domains, such as Bax, Bak, and
Bok. Members of the third subfamily, also referred to as
“BH3-only” proteins, lack BH1, BH2, and BH4 cassettes and
are characterized by a single BH3 domain. Members of this
family are proapoptotic Bid, Bim, Bad, Bik/Blk/Nbk, Mule,
Hrk/DP5, Puma/Bbc3, and Noxa (see Figure 1 for schematic
representation of mammalian, viral, and C. elegans Bcl-2
proteins).
Over the past two decades, cell culture and animal
studies exploited the roles of Bcl-2 family proteins as pro-
and antiapoptotic mitochondrial eﬀectors in carcinogenesis
and therapy resistance. Bcl-2 family proteins are critical
regulators of the intrinsic, that is, mitochondria-dependent
apoptotic pathway. Sharply contrasting the extrinsic path-
way, which is instigated by death receptor (DR) ligation
and activation of initiator caspases 8, 10, and 2 [7], the
intrinsic pathway is triggered by chemotherapeutic drugs,
developmental cues, and growth deprivation and culminates
in the disintegration of inner and outer mitochondrial
membranes and the release of apoptogenic factors from
mitochondria into the cytoplasm, most notably cytochrome
c (cyt c) [3]. Bcl-2 family members regulate mitochon-
drial membrane homeostasis, by promoting or inhibiting
mitochondrial outer membrane permeabilization (MOMP),
and consequently the release of proapoptotic mitochondrial
factors [8]. Antiapoptotic members, such as Bcl-2 and
Bcl-xL, are embedded into organelle membranes, most
importantly the outer mitochondrial membrane, where
they can bind their BH3-only prodeath relatives, such as
caspase-activated Bid, termed truncated Bid (tBid). tBid
displaces multi-BH domain-containing proapoptotic death
agonists,suchasBadandBax,fromaheterodimericcomplex
with Bcl-2 or Bcl-xL. Once released, Bad/Bax oligomerize
and insert into the outer mitochondrial membrane to
induce MOMP [8]. Mechanistically, a Bax:BH3 alpha-helix
interaction triggers conformational changes within the Bax
polypeptide, mobilizing a carboxy-terminal alpha helix for
membrane translocation and exposing the BH3 domain
of Bax, which subsequently interacts with an internal Bax
activation site to activate monomeric Bax [9]. Subsequently,
mitochondrial proteins, foremost cyt c, are released into
the cytosol where they induce caspase activation. By anal-
ogy to membrane-bound DRs acting as scaﬀold proteins
to promote caspase maturation, the apoptotic protease-
activating factor (Apaf-1) assembles a cytosolic, multimeric
structure to enable caspase-9 activation in the presence
of cyt c and ATP [10]. Once activated, caspase-9 cleaves
downstream caspases, most importantly, eﬀector caspase-3
a n d- 7 ,w h i c hi nt u rns e l e c t i v e l yc l e a v ea n di n a c t i v a t ec e l l u l a r
proteins to induce and propagate cellular demise. Besides
cyt c, second mitochondria-derived activator of caspases
(SMAC)/direct inhibitor of apoptosis-binding protein with
low pI (DIABLO) and Omi represents a second class of pro-
death, apoptogenic factors that are released during MOMP
into the cytosolic compartment. They prevent inhibitor
of apoptosis proteins (IAPs) from binding and inhibiting
postmitochondrial caspases 9, 3, and 7 [11].
Bcl-2 was ﬁrst identiﬁed as a deregulated oncogene in
follicular B-cell lymphomas, where it is placed under the
control of the immunoglobulin heavy-chain promoter by
a t(14;18) chromosome translocation. While canonical Bcl-
2 proteins play pivotal and well-deﬁned roles in several
cancers, including B-cell lymphoma, breast carcinomas,
and melanoma, their impact on gliomagenesis is less well
understood. During progression from initial to recurrent
GBM, the Bcl-2 rheostat was demonstrated to shift towards
an antiapoptotic setting, which favored resistance [12]. In a
mouse model of oligodendroglioma, coexpression of PDGF-
B and Bcl-2 promoted tumor growth and progression to
anaplastic disease. Such progression was associated with
reduced tumor latencies, increased intratumoral prolifera-
tion, and decreased apoptosis rates [13]. Counterintuitively
and similar to other malignancies, including mammary
and gastric carcinomas, overexpression of antiapoptotic
members is more often found in lower-grade tumors
than in high-grade gliomas [14] and has repeatedly been
associated with a more favorable prognosis [15]. Similarly,
high levels of proapoptotic Bax have been observed in
advanced gliomas, and to a lesser extent in earlier-stage
neoplasms [16]. Although further experimental evidence
is required to conclusively address this conundrum, it is
conceivable that sustained survival linked to high Bcl-2
expression may reduce the selection pressure to acquire
further genetic mutations associated with advanced tumor
progression. Another explanation is that Bcl-2 has anti-
growth activities, as it delays cell cycle progression through
upregulation of the CDK inhibitor, p27, and downregu-
lation of phosphorylated Rb and functional E2F proteins.The Scientiﬁc World Journal 3
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Figure 1:TheBcl-2family.Domainstructureofmammalian,viral,andC.elegansproteins.Shownareantiapoptotic“core”proteins,atypical
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Accordingly, lymphomas with elevated Bcl-2 levels show
lower proliferative capacities, suggesting that the impact of
Bcl-2 on G0 to S phase transition is physiologically relevant
[17] and that high-grade gliomas may escape cell cycle
block by downregulating Bcl-2 expression. Furthermore,
antiapoptotic Bcl-2 can induce apoptosis when bound to
orphan nuclear receptor Nur77/TR3. Binding of Bcl-2 to
Nur77 induces a Bcl-2 conformational change that exposes
its BH3 domain, transforming Bcl-2 into a proapoptotic
protein [18]. Correspondingly, Bax can act as a potent
inhibitor of apoptosis in neurons of mice infected with
Sindbis virus [19]. Other studies reporting bimodal activ-
ity proﬁles of Bcl-2 family members identiﬁed Bak as a
cell-type-speciﬁc anti- or proapoptotic protein in neurons
depending on neuronal subtype and postnatal development
stage [20] and proapoptotic Bid as a pro-survival factor, as
its phosphorylation by ATM redirects the cellular program
from apoptosis to S phase arrest to allow for DNA repair
rather than cell death induction [21, 22]. Finally, Bcl-2 has
promigratory and proinvasive activities, as Bcl-2-expressing
glioma cell lines exhibited enhanced expression and activity
of the proprotein convertase furin, which proteolytically
activates proinvasive metalloproteinases (MMP) and TGF-
β [16]. Further molecular insights into these bimodal activ-
ities of Bcl-2 family proteins in glial cells will advance our
understanding of the contribution of Bcl-2 family proteins
to gliomagenesis.
In addition, the constitutively active form of EGFR,
termed EGFRvIII, resulting from a deletion of exons 2 to
7, inhibited therapy-induced apoptosis via upregulation of
Bcl-xL andsubsequentblockageofeﬀectorcaspaseactivation
[23]. In addition, EGFR and EGFRvIII can interact with
Puma, resulting in cytoplasmic sequestration and inac-
tivation of Puma [24]. Furthermore, studies in nonglial
tumor cells have identiﬁed important signaling concepts
linking RTK inhibition to apoptosis signal transduction.
Erlotinib and geﬁtinib induced apoptosis in small cell lung
cancer cell lines and derived xenografts via upregulation of
Bim [25–29]. The Mek-Erk1/2-Notch signaling pathway can
induce Bim mRNA and protein synthesis, and consistently,
pharmacological inhibition of Mek-1/2 led to upregulation
of Bim. Additional studies showed that blockage of the
PI3K signaling arm provoked downregulation of Mcl-1,
suggesting that the Bcl-2 protein rheostat might determine
resistance and sensitivity to inhibition of RTKs and canon-
ical downstream signaling [25, 28, 30]. Similar detailed
biochemical and genetic studies analyzing cellular and
molecular responses to RTK inhibition are still pending for
glioma cells and derived tumors: Is the Bim/Mcl-1 rheostat
important for determining sensitivity of GBM tumors to
RTK inhibition? Does inhibition of diﬀerent RTKs converge
on Bim upregulation to induce apoptosis or do individual
RTKs induce a unique transcriptomic and proteomic signa-
ture? Do tumors that are resistant toward RTK inhibitors
express antiapoptotic Bcl-2 family members to block Bim-
instigated MOMP? Are elevated Bim levels a consequence of
transcriptional induction or posttranslational stabilization?
Detailed transcriptomic and proteomic surveys of glioma
cells and tumors treated with diﬀerent combinations of
inhibitorstargetingRTKsanddownstreamRas/Mek/Erkand
PI3K/Akt/mTOR signaling will provide important answers.
More recently, comprehensive oncogenomic and tissue
microarrayanalysesvalidatedrobustampliﬁcation(nonfocal
gain of chromosome 19q13) and overexpression of the
noncanonical Bcl-2 family protein, Bcl-2-Like 12 (Bcl2L12)
in primary GBM tumor specimens. In contrast, Bcl2L12
exhibited low or undetectable levels in cells of glial origin
in normal brain surrounding tumor tissue or in low-
grade astrocytoma [31]. Bcl2L12 lacks BH1, BH3, BH4,
and transmembrane motifs and is characterized by a single,
carboxy-terminal BH2 domain (Figure 1)[ 32]. In addition,
the Bcl2L12 polypeptide contains a proline-rich region
with homology to known oncogenes, such as RRas, and
several PxxP tetrapeptide motifs, documenting that Bcl2L12
represents a structurally distinct Bcl2L12 family protein [31,
32]. Does Bcl2L12 impact MOMP similar to canonical Bcl-2
proteins, or does its atypical domain structure translate into
atypical functional properties?
3. The Black Sheep Bcl2L12: The Bcl-2
FamilyMeets PostmitochondrialCaspase
andNuclear p53 Signaling
Detailed functional studies in primary and transformed glial
cells and derived orthotopic explants identiﬁed Bcl2L12 as
a potent inhibitor of postmitochondrial eﬀector caspase
activationandthep53tumorsuppressoractivity.Speciﬁcally,
enforcedexpressionofBcl2L12inprimarycorticalastrocytes
enhanced cellular growth, conferred marked apoptosis resis-
tancetowardchemo-andradiationtherapies,yetengendered
cellular necrosis and eﬀected malignant transformation [31].
In addition, RNAi loss-of-function studies demonstrated
that Bcl2L12 neutralization sensitized glioma cells toward
apoptosis,andmostimportantly,reducedintracranialtumor
formation with increased apoptotic, decreased proliferative
indices, and enhanced tumor-free survival [31]. On the
biochemical level, these oncogenic actions related signiﬁ-
cantly to the capacity of Bcl2L12 to inhibit apoptosis by
neutralizing eﬀector caspase-3 and -7 activity downstream of
mitochondrial dysfunction and apoptosome activity [31, 33,
34]. Intriguingly, postmitochondrial caspase activation acts
as a molecular switch between apoptotic and necrotic cell
death: due to mitochondrial dysfunction and cytochrome c
release in the context of concomitantly neutralized eﬀector
caspase activation, respiratory function and consequently
intracellular ATP levels decrease; ion homeostasis can no
longer be maintained, provoking cellular edema, dissolution
of organelles, and rapture of the plasma membrane [35].
Indeed,Bcl2L12expressionpromotednecrosisinresponseto
apoptotic stimulation [31]. In addition, Bcl2L12 physically
interacts with and neutralizes the transactivational activity
of the p53 tumor suppressor protein by abrogating p53
binding to its target gene promoters. Bcl2L12-mediated
neutralization of p53 activity enabled glioma cells to bypass
p53-dependent replicative senescence and inhibited DNA
damage-induced apoptosis. In addition, Bcl2L12 blocked
p53’s capacity to bind to certain target promoters andThe Scientiﬁc World Journal 5
attenuated p53-mediated induction of selected target genes,
including the cell cycle inhibitor p21 and the proapoptotic
Bcl-2 family proteins Bax, Puma, and Noxa [36, 37].
By blocking apoptosis and p53 signaling and redirecting
the death program to necrosis, the molecular proﬁle of
Bcl2L12 provides a rational molecular explanation for hall-
mark features of GBM—that is, apoptosis resistance, ﬂorid
necrosis, and soaring proliferation—and points to Bcl2L12
upregulation as a key progression event in malignant glioma.
Recent in-depth analyses of the TCGA (The Can-
cer Genome Atlas) dataset, a comprehensive catalogue of
genomicandgeneticaberrationsobservedinGBM,classiﬁed
tumor specimens according to their molecular signature into
classical, mesenchymal, proneural, and neural subgroups
[38, 39]. The Classical group is characterized by increased
ampliﬁcation/expression and mutation of the epidermal
growth factor receptor (EGFR), deletion of PTEN and
INK4A, and deregulation of retinoblastoma (Rb) pathway
components (RB1, CDK4, and CCDN2 genes). The mes-
enchymal group exhibits loss of the tumor suppressor NF1
and increased levels of NF-κB signaling molecules, for
example, TRADD. Elevated expression of neuronal markers,
such as NEFL and GABRA1, mainly characterizes the neural
subclass. Finally, proneural tumors show alterations in the
PDGFR, IDH1, and TP53 as well as high expression of
oligodendrocytic development genes, such as PDGFRA,
NKX2-2, and OLIG2. Importantly, Bcl2L12 exhibited low-
level ampliﬁcation and expression in the proneural class
harboring p53 pathway mutations, and higher ampliﬁcation
and expression in EGFR-driven classical and mesenchymal
subtypes [36, 37], suggesting that tumors with already inca-
pacitated p53 signaling circumvent the need for additional
gain of the p53 inhibitor Bcl2L12, thus providing genetic
evidence of a Bcl2L12-p53 axis in GBM. Coexpression of
Bcl2L12 and EGFR also raises the possibility that EGFR and
Bcl2L12 signaling cooperate to drive gliomagenesis. Future
studies will test this provocative hypothesis.
4.Targeting the Bcl-2 Familyto
Block GBMProgression
Several small molecules have been synthesized that act as
BH3 mimetics to disarm antiapoptotic Bcl-2 and Bcl-xL by
preventing their heterodimerization with, and inactivation
of, their proapoptotic relatives. This class of apoptosis
inhibitors includes BH3I-1, HA14-1antimycin A, gossypol
(NSC19048), apogossypol (NSC736630), obatoclax (GX15-
070), chelerythrine, TW-37, 4-(3-methoxyphenylsulfonyl)-
7-nitro-benzofurazan-3-oxide (MNB), TM12-06, ABT-737
and the related orally active derivative ABT-263, and
pyrogallol-based molecules. While the exact target speciﬁcity
remains elusive for most of these compounds, many preclin-
ical and clinical studies have documented potent antitumor
activities, primarily in lymphoid malignancies.
Only three Bcl-2 mimetics, HA-14-1, ABT-737, and
gossypol have been evaluated as putative antiglioma
therapeutics. HA-14-1 and ABT-737, which are the most
potent BH3 mimetic with high aﬃnity (Ki ≤ 1) to Bcl-2,
Bcl-xL, and Bcl-w, induce apoptosis in glioma cell lines by
promoting the release of proapoptotic Bax from a Bax:Bcl-2
heterodimeric complex [40, 41]. In addition, ABT-737-
and HA-14-1-treated glioma-bearing mice showed reduced
tumor formation and increased survival, suggesting that
targeting Bcl-2/Bcl-xL/Bcl-w alone or in combination
with chemotherapy and radiation regimens represents
a promising therapeutic approach. Of note, resistance to
ABT-737hasmainlybeenlinkedto highexpressionofMcl-1,
suggesting that dual inactivation of Bcl-2/Bcl-xL/Bcl-w and
Mcl-1 signaling axes is obligatory for substantial apoptosis
induction. Expectedly, RNAi-mediated downregulation
of Mcl-1 in glioma cell lines and stem cells was found to
increase sensitivity to ABT-737-induced apoptosis [40].
While ABT-737 is a highly selective BH3 mimetic,
gossypol has activities in addition to binding to the BH3
pocket of antiapoptotic Bcl-2/Bcl-xL. These include associ-
ation or intercalation into plasma and mitochondrial mem-
branes, which results in lipid condensation/damage, gradual
mitochondrial swelling, structural distortion of the inner
mitochondrial membrane, and dissipation of ΔΨM [42].
Early clinical studies with gossypol revealed little toxicity
and low, but measurable response rates in patients with
grade III and grade IV astrocytomas [43]. Current clinical
trials (NCT00540722, NCT00390403) aim to assess tumor
response rates and dosage/toxicity in combination with
TMZ/radiation. These trials will provide the ﬁrst evidence
as to whether Bcl-2 protein inhibition mediates antiglioma
activity in vivo.
Additional strategies to target Bcl-2 family proteins,
not all of which have been tested in malignant glioma,
include antisense approaches and diverse compounds such
as tetrocarcin A (TC-A), antimycin A3, chelerythrine, and
WP1066 [44, 45]. WP1066 selectively inhibits the STAT3
pathway and reduces STAT3-driven expression of Bcl-2, Bcl-
xL, and Mcl-1, triggering Bax activation [46] and resulting in
extended survival of xenogeneic glioma mouse models [47].
Of particular interest are hydrocarbon-stapled, alpha-helical
BH3 peptides, which bind with high aﬃnity to multidomain
Bcl-2 members, are protease-resistant, and potently induce
apoptosis in leukemia cells and derived explants [48].
Research over the last ﬁve years established microR-
N A s( m i R N A s )a si m p o r t a n tr e g u l a t o r so fg l i o m a g e n e s i s .
miRNAs are small, noncoding RNAs that can repress
gene expression by either directly binding and inducing
degradation of target mRNAs or by inhibiting translation
[49]. Speciﬁcally, miR-153 has been identiﬁed as a negative
regulator of Bcl-2 and can induce cell death in GBM [50].
Conversely, overexpression of miR-21 was reported to reduce
Bax levels in GBM and protect glioma cell lines from TMZ-
induced apoptosis [51]. Therefore, enforced expression of
miR-153 or targeting miR-21 with synthetic inhibitors could
sensitize glioma cells to therapy-induced apoptosis.
Additional approaches focused on the overexpression of
proapoptotic molecules, for example, Bax and Bik. Aden-
oviral expression of Bik neutralized Bcl-2 and Bcl-xL and
induced p53- and caspase-independent cell death in GBM
cell lines. This strategy, however, was limited by signiﬁcant
toxic eﬀects of Bik overexpression to the surrounding glial6 The Scientiﬁc World Journal
and neuronal cells [52]. Similarly, Bax overexpression in-
duced apoptosis in glioma cell lines and increased their
sensitivity toward radiation therapy [53, 54].
5. Inhibitors of the Bcl-2 Protein Family for
the Treatment of GBM—FuturePerspectives
Antiapoptotic Bcl-2 proteins, for example, prototypic Bcl-
2 and Bcl-xL, are commonly upregulated in human cancers
and counteract the activity of their proapoptotic relatives,
which are induced as potent tumor suppressors during
cancer progression. Numerous studies evaluated expression
levels of canonical Bcl-2 family proteins in hematological
malignancies and certain solid neoplasms. In particular, Bcl-
2 was shown to be upregulated in chronic lymphocytic
leukemia, diﬀuse large B-cell lymphomas, mantle cell lym-
phomas, and diverse solid tumors, including neuroblastoma;
Bcl-xL overexpression is important for multiple myelomas;
Mcl-1 has been implicated in the genesis of acute myeloid
leukemia, cholangiocarcinomas, and follicular lymphomas;
A1 is expressed in B-cell lymphomas and chronic myeloid
leukemia, and high protein abundance of Bcl-w was dis-
covered in advanced-stage colorectal adenocarcinomas [55].
A more detailed expression survey of these Bcl-2 pro-
teins in malignant glioma, in particular the assessment of
their inducible expression upon (targeted) drug treatment,
remains elusive.
Given the prominence of antiapoptotic Bcl-2 proteins in
driving tumorigenesis and shaping therapy responses, BH3
mimetics emerged as potent antineoplastic therapeutics,
either alone or in combination with other modalities, such
as DNA-damaging agents. Importantly, ABT-737 and ABT-
263 target Bcl-2 and Bcl-xL, but not Mcl-1 [56]. Thus, the
development of Mcl-1-speciﬁc inhibitors remains a high-
priority area of investigation. In addition, the elucidation of
the precise activation mechanism of proapoptotic Bcl-2 fam-
ily protein, foremost Bax and Bak, and their transcriptional
andposttranslationalregulationwillmostcertainlyguidethe
development of targeted agents to speciﬁcally activate these
proteins.
Besides small-molecule-based approaches to inactivate
antiapoptotic Bcl-2 family proteins, RNAi emerged as a pow-
erful technology, to neutralize expression of Bcl-2, Bcl-xL,
or Bcl2L12, to sensitize glioma cells toward therapy-induced
apoptosis and to reduce intracranial tumor formation in
xenogeneic explant models [31, 57].
Notably, the systemic delivery of small molecules and
RNAs is limited by the low permeability of the BBB/BTB
and is often associated with signiﬁcant cytotoxic eﬀects to
non-cancer cells. The recent development of innovative nan-
otechnological agents to speciﬁcally and eﬀectively deliver
cytotoxic drugs or small RNA molecules to glioma, but
not adjacent normal cells, promises to be transformative
for neurooncology research. A recent approach developed
by Bhatia and colleagues employed dendrimer-conjugated
magnetoﬂuorescent nanoconstructs (called “dendriworms”)
as a platform to deliver siRNA in vivo. These dendriworms
arenontoxic,bypasstheBBB,arereadilyinternalizedbycells,
and can achieve gene knockdown in an acute-onset GBM
mouse model in vivo [58]. Another recent study by Ding
and colleagues delivered antisense oligonucleotides (AONs)
targeting laminin-411 to xenogenic glioma explants using a
poly (β-L-malic acid) nanobioconjugate. This nanomaterial
was functionalized with a monoclonal antibody against
transferrin receptor (TfR) to facilitate penetration of the
BBB and BTB. Intravenous delivery of AON nanoconjugates
resulted in potent, glioma-speciﬁc knockdown of lamin-
411 and, consequently, robust reduction in tumor formation
[59]. Future studies will focus on similar delivery systems to
neutralize expression of antiapoptotic Bcl-2 family proteins,
foremost Bcl-2, Bcl-xL, Mcl-1, and Bcl2L12.
Finally, it will be important to understand the role(s) of
Bcl-2 proteins in the maintenance and therapy resistance of
glioma stem cells (GSCs), a small cell population embedded
within GBM tissue that undergoes self-renewal in culture,
forms tumors in orthotopic transplants in vivo,c a ng e n e r a t e
a diversiﬁed neuron-like and glia-like postmitotic progeny,
and is thought to play important roles in GBM recurrence
[60]. The key questions are: what are the expression patterns
of Bcl-2 family proteins in GSCs? Do Bcl-2 family proteins
regulate therapy resistance of GSCs, and if so, what are the
underlying molecular mechanisms? A recent study began
to address these questions and demonstrated that ATF-5-
dependent upregulation of Mcl-1 plays critical roles in GSC
survival in response to targeted therapies [61].
The molecular characterization of Bcl-2 family continues
to establish novel links between Bcl-2 proteins and diverse
cellular processes, such as the regulation of mitochondrial
energy metabolism and dynamics, glucose metabolism,
autophagy, p53 function, calcium signaling, GSC homeosta-
sis, and therapy responses [62]. Such detailed molecular
characterization, together with more detailed studies of the
roleofBcl-2familyproteinsingliomapathogenesis,foremost
the generation of Bcl-2 protein-driven, inducible gain- and
loss-function glioma mouse models, and the development of
novel (nano-) technologies to eﬀectively deliver therapeutics
targeting the Bcl-2 protein family into intracerebral tumors,
promise to be transformative for glioma research in the near
future.
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